Merus N.V. (MRUS Quick QuoteMRUS - Free Report) shares ended the last trading session 13% higher at $25.48. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2% gain over the past four weeks.

Investors are upbeat about the company’s new collaborations in Israel, Italy and Spain to expand molecular screening opportunities for cancer patients that may have neuregulin 1 (NRG1) fusions and to raise awareness of the eNRGy clinical trial of its bispecific antibody zenocutuzumab (Zeno).

Price and Consensus

This company is expected to post quarterly loss of $0.60 per share in its upcoming report, which represents a year-over-year change of -1.7%. Revenues are expected to be $7.83 million, up 17.4% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Merus N.V., the consensus EPS estimate for the quarter has been revised 13.8% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on MRUS going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>